Search results for "bladder"

showing 8 items of 628 documents

Intravesical chemotherapy for intermediate risk non-muscle invasive bladder cancer recurring after a first cycle of intravesical adjuvant therapy

2015

Context: The therapeutic strategy in intermediate risk (IR) non-muscle invasive bladder cancer (NMIBC) recurring after intravesical therapy (IT) is not well defined. Most patients are usually retreated by Bacillus Calmette-Guerin (BCG). Aims: To evaluate the efficacy of intravesical chemotherapy (ICH) given at recurrence after the first cycle of ICH in IR-NMIBC recurring 6 months or later. Settings and Design: Retrospective analysis of the efficacy of ICH given after previous IT. Materials and Methods: The clinical files of IR-NMIBC patients recurring later than 6 months after transurethral resection (TUR) and IT and retreated by IT were reviewed. The patients should be at intermediate risk…

medicine.medical_specialtyrecurrenceUrologyContext (language use)intermediate risklcsh:RC870-923Settore MED/24 - UrologiaCytologyintravesical chemotherapyAdjuvant therapyMedicinecardiovascular diseasesBacillus Calmette-GuerinBladder cancermedicine.diagnostic_testbusiness.industryProportional hazards modelCystoscopylcsh:Diseases of the genitourinary system. Urologymedicine.diseaseSurgerynervous system diseasesBacillus Calmette-Guerin intermediate risk intravesical chemotherapy non muscle invasive bladder cancer recurrenceMann–Whitney U testnon muscle invasive bladder cancerOriginal ArticlebusinessIntravesical chemotherapyUrology Annals
researchProduct

An Anti-Ubiquitin Antibody Response in Transitional Cell Carcinoma of the Urinary Bladder

2015

BackgroundTo use combinatorial epitope mapping ("fingerprinting") of the antibody response to identify targets of the humoral immune response in patients with transitional cell carcinoma (TCC) of the bladder.MethodsA combinatorial random peptide library was screened on the circulating pool of immunoglobulins purified from an index patient with a high risk TCC (pTa high grade plus carcinoma in situ) to identify corresponding target antigens. A patient cohort was investigated for antibody titers against ubiquitin.ResultsWe selected, isolated, and validated an immunogenic peptide motif from ubiquitin as a dominant epitope of the humoral response. Patients with TCC had significantly higher anti…

medicine.medical_treatmentScienceUrinary Bladderurologic and male genital diseasesEpitopeImmune systemAntigenmedicineHumansddc:610Carcinoma Transitional CellMultidisciplinarybiologybusiness.industryUbiquitinQAntibody titerRImmunotherapymedicine.diseaseTiterTransitional cell carcinomaUrinary Bladder NeoplasmsImmunologyAntibody Formationbiology.proteinMedicineAntibodybusinessEpitope MappingResearch ArticlePLoS ONE
researchProduct

Efficacy of one-year maintenance in early adjuvant chemotherapy for intermediate risk non-muscle-invasive bladder cancer. Preliminary results of a ra…

2008

Introduction and Objective: The clinical value of early intravesical adjuvant chemotherapy after TUR of intermediate risk non-muscle-invasive bladder cancer (NMI TCCB) is well established. On the other hand, the optimal schedule regimen and the role of maintenance are still debated. The aim of the present study was to evaluate the effectiveness of one-year maintenance schedule in patients submitted to TUR plus adjuvant early intravesical chemotherapy. Methods: Between May 2002 and August 2003, 577 patients, were recruited. All patients underwent TUR and early (within 6 hours) intravesical chemotherapy with epirubicin at the dose of 80 mg diluted in 60 ml of saline solution. When histology w…

non-muscle-invasive bladder cancer adjuvant chemotherapy
researchProduct

Mandibular metastasis from carcinoma of the bladder: Report of a case and literature review

2022

Metastases represent about 1% of all malignant tumors of the oral region. Only 12 cases of metastases to the jawbones and 3 to the oral soft tissues from a carcinoma of the bladder are reported in the English literature. Here we report a case of an 86 year-old man with a metastasis to the anterior region of the lower jaw from a transitional cell carcinoma of the bladder treated 5 years before, all-together with a literature review.

stomatognathic diseasesTransitional cell carcinomaCARCINOMABladderOral metastasisMandibular metastasisNEOPLASIAS MANDIBULARESGeneral DentistryCARCINOMA DE CELULAS ESCAMOSASUNESCO:CIENCIAS MÉDICASJournal of Clinical and Experimental Dentistry
researchProduct

Modified Glasgow Prognostic Score is Associated With Risk of Recurrence in Bladder Cancer Patients After Radical Cystectomy

2015

Recently, many studies explored the role of inflammation parameters in the prognosis of urinary cancers, but the results were not consistent. The modified Glasgow Prognostic Score (mGPS), a systemic inflammation marker, is a prognostic marker in various types of cancers. The aim of the present study was to investigate the usefulness of the preoperative mGPS as predictor of recurrence-free (RFS), overall (OS), and cancer-specific (CSS) survivals in a large cohort of urothelial bladder cancer (UBC) patients.A total of 1037 patients with UBC were included in this study with a median follow-up of 22 months (range 3-60 months). An mGPS = 0 was observed in 646 patients (62.3%), mGPS = 1 in 297 pa…

to-lymphocyte ratioAdultMaleRiskmedicine.medical_specialtyPrognosimedicine.medical_treatmentCystectomyGastroenterologySettore MED/24 - UrologiaCystectomyMedicine (all); c-reactive protein; advanced urothelial carcinoma; to-lymphocyte ratioc-reactive proteinRetrospective StudieInternal medicine80 and overHumansMedicineStage (cooking)advanced urothelial carcinomaRetrospective StudiesAgedAged 80 and overModified Glasgow Prognostic Score is Associated With Risk of Recurrence in Bladder Cancer Patients After Radical Cystectomy: A Multicenter Experience.Univariate analysisBladder cancerbusiness.industryProportional hazards modelMedicine (all)Hazard ratioBladder cancer Radical cystectomyRetrospective cohort studyGeneral MedicineMiddle AgedPrognosismedicine.diseaseSurgeryNeoplasm RecurrenceLocalUrinary Bladder NeoplasmsUrinary Bladder NeoplasmCohortFemaleNeoplasm Recurrence LocalAdult; Aged; Aged 80 and over; Female; Humans; Male; Middle Aged; Neoplasm Recurrence Local; Prognosis; Retrospective Studies; Risk; Urinary Bladder Neoplasms; Cystectomy; Medicine (all)businessHumanMedicine
researchProduct

Identification of omic profiles for diagnosis and monitoring of bladder cancer

2019

La presente Tesis titulada Identificación de perfiles ómicos para el diagnóstico y la monitorización del cáncer de vejiga se centra en la identificación de biomarcadores metabolómicos urinarios no invasivos para el diagnóstico y la monitorización del cáncer de vejiga (CaV). Con este fin, se han utilizado dos plataformas analíticas: la Resonancia Magnética Nuclear (Nuclear Magnetic Resonance, 1H NMR) y la Cromatografía Líquida de alta resolución acoplada a la Espectrometría de Masas (Ultraperformance Liquid Chromatography–Mass Spectrometry, UPLC-MS). Además, se han analizado tejidos vesicales mediante la técnica de Resonancia Magnética Nuclear de Alta Resolución con Giro de Ángulo Mágico (Hi…

transcriptomicsnuclear magnetic resonanceUNESCO::CIENCIAS MÉDICASbladder cancermetabolic pathways:CIENCIAS MÉDICAS [UNESCO]metabolomicsmass spectrometry
researchProduct

Changes in the receptor profile of the lower urinary tract in the aging male

2004

Benign prostatic hyperplasia (BPH) is one of th e most common effects of aging in men. Epidemiologists estimate that about one quarter of all men over 50 years of age suffer from BPH-derived voiding symptoms. Future demographic developments, with higher relative shares of older people, will increase the socioeconomic impact of this disease. Polder et al. (1994) calculated for the Netherlands that the treatment costs of BPH will double by 2035. Office visits for BPH related symptoms increased in the USA from 1.4 million in 1990 to 6 million in 1995, reflecting the increased public awareness of the problem and the increased desire for treatment (Kaplan et al. 1996).

urogenital systembusiness.industryAging maleUrinary systemDiseaseHyperplasiaurologic and male genital diseasesQuarter (United States coin)medicine.diseaseBladder outlet obstructionmedicinebusinessOlder peopleSocioeconomic statusDemography
researchProduct

Bladder tumours in children: An interesting case report of TCC with a partial inverted growth pattern.

2014

Bladder urothelial carcinoma is typically a disease of older individuals and rarely occurs below the age of 40 years. There is debate and uncertainty in the literature regarding the clinicopathologic and prognostic characteristics of bladder urothelial neoplasms in younger patients compared with older patients, although no consistent age criteria have been used to define "younger" age group categories. We report on a 16 years old girl with transitional cell carcinoma of the bladder with a partial inverted growth pattern who presented with gross hematuria. Ultrasonography revealed a papillary lesion in the bladder; cystoscopic evaluation showed a 15 mm papillary lesion with a thick stalk loc…

young adultsmedicine.medical_specialtyBladder Urothelial CarcinomaUrologyPapillary lesionUrologyInverted papillomalcsh:RC870-923urologic and male genital diseasesinverted papillomaOlder patientsPathologymedicineYoung adultBladder cancerbusiness.industryBladder cancerlcsh:Diseases of the genitourinary system. Urologymedicine.diseasefemale genital diseases and pregnancy complicationsTransitional cell carcinomabladder cancerpathologyUltrasonographybusinessbladder cancer; young adults; inverted papilloma; pathologyInverted papillomaYoung adultsArchivio italiano di urologia, andrologia : organo ufficiale [di] Societa italiana di ecografia urologica e nefrologica
researchProduct